Patent Application Reveals New Cancer Treatment Using Dendritic Cells with Silenced Dab2 Gene

Strategic Insights -

Scientists at the Research & Business Foundation Sungkyunkwan University have made a breakthrough in cancer treatment, filing a patent for a pharmaceutical composition that uses dendritic cells with a silenced Dab2 gene to prevent or treat cancer. The application, filed on November 7, 2014, and made available online on October 15, 2015, outlines a method to suppress Dab2 gene expression in dendritic cells, increasing the cells' ability to stimulate an immune response against cancer.

Key Takeaways:

  • The patent application describes a pharmaceutical composition that includes dendritic cells with suppressed Dab2 gene expression.
  • The composition is designed to increase the cells' ability to stimulate an immune response against cancer.
  • The method involves using siRNA, antisense nucleotides, or other means to suppress Dab2 gene expression in dendritic cells.
  • The composition is intended for use in treating various types of cancer, including bladder cancer, bone cancer, blood cancer, and others.
  • The researchers found that suppressing Dab2 gene expression in dendritic cells increased T cell proliferation and antigen-specific cytotoxic T cell lymphocytes (CTLs).
  • The patent application reports the use of various techniques, including western blot analysis, qRT-PCR, and MTI analysis, to study the effects of Dab2 gene silencing on dendritic cells.
  • The researchers found an increase in cytokines and a decrease in cell migration in dendritic cells with silenced Dab2 gene expression.
  • The application reports the efficacy of the composition in treating cancer in E.G7 and EL4 mouse models.

Statistics:

  • The patent application was filed on November 7, 2014.
  • The patent was made available online on October 15, 2015.
  • The application reports an increase in T cell proliferation.
  • The researchers found an increase in antigen-specific cytotoxic T cell lymphocytes (CTLs).
  • The composition is intended for use in treating 22 types of cancer.
  • The patent application reports the use of various techniques, including western blot analysis, qRT-PCR, and MTI analysis.

Sources:

  • BAE, Yong-Soo; BYEON, Se Eun; AHMED, Selim; JEONG, Yideul. Pharmaceutical Composition for Preventing Or Treating Cancers Comprising Dendritic Cells with Dab2 Gene Silenced. Filed November 7, 2014 and posted October 15, 2015. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6256&p=126&f=G&l=50&d=PG01&S1=20151008.PD.&OS=PD/20151008&RS=PD/20151008